Medpace/$MEDP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
- Ticker
- $MEDP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,500
- Headquarters
- Cincinnati, United States
- Website
- www.medpace.com
Medpace Metrics
BasicAdvanced
$17B
36.26
$17.06
1.15
-
Price and volume
Market cap
$17B
Beta
1.15
52-week high
$677.90
52-week low
$373.00
Average daily volume
249K
Financial strength
Current ratio
0.732
Quick ratio
0.658
Long term debt to equity
0.277
Total debt to equity
0.277
Profitability
EBITDA (TTM)
611.2
Gross margin (TTM)
72.35%
Net profit margin (TTM)
17.67%
Operating margin (TTM)
20.97%
Effective tax rate (TTM)
17.94%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
20.10%
Return on equity (TTM)
162.15%
Valuation
Price to earnings (TTM)
36.258
Price to revenue (TTM)
6.281
Price to book
39.79
Price to tangible book (TTM)
-65.97
Price to free cash flow (TTM)
24.728
Free cash flow yield (TTM)
4.04%
Free cash flow per share (TTM)
25.011
Growth
Revenue change (TTM)
24.67%
Earnings per share change (TTM)
26.75%
3-year revenue growth (CAGR)
18.48%
10-year revenue growth (CAGR)
23.12%
3-year earnings per share growth (CAGR)
26.83%
10-year earnings per share growth (CAGR)
109.83%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Analyst projections of the future price of Medpace stock.
Bulls say / Bears say
Net new business awards rose 28.2% year on year to $795.7 million, giving Medpace a 1.13 book-to-bill ratio and lifting backlog to about $3.0 billion. That points to renewed demand and helps replenish work for future revenue. (Medpace)
Second-quarter revenue grew 17.2% and net income rose 34.5%, while the company forecast 10.9% to 14.0% revenue growth for 2026. Strong delivery and a double-digit full-year outlook support the earnings-growth case. (Medpace)
Management said requests for proposals increased both sequentially and year on year, with cancellations lower and the business environment constructive into July. A healthier flow of trial opportunities could support bookings beyond the latest quarter. (ROIC AI)
UBS says Medpace trades at the highest valuation among CRO peers, limiting scope for further multiple expansion. That leaves less room for disappointment if results merely meet already reasonable expectations. (StreetInsider)
Backlog rose only 4.9% year on year to $3.0 billion, versus 17.2% revenue growth in the quarter. UBS warns backlog coverage has fallen, so Medpace needs to keep winning work to avoid a future slowdown. (Medpace, StreetInsider)
Medpace relies heavily on a small group of sponsors: its top five customers generated about 31% of trailing-year revenue and its top ten 40%. Management also said cancellations are difficult to predict, leaving results exposed if major clients cut or stop trials. (ROIC AI)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2026.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Upcoming events
No upcoming events
Medpace News
AllArticlesVideos
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Business Wire4 weeks ago
Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
Investors Business Daily2 months ago
Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
Benzinga3 months ago
Funds containing Medpace
AllUSDEURGBP
Fund name | Fund size | $MEDP weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.51% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.51% |
iShares Healthcare Innovation£DRDR | £1B | 1.51% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.17% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.